The above-mentioned associations of HDACs with other factors could serve for combinatorial optimization of new potential therapeutic targets; for example, the combination of tamoxifen with an HDAC-6 inhibitor for patients with ER positive HDAC-6 expressing kidney tumors [71]. Here, HDAC6 is linked to kidney neoplasm.